Stockreport

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of ...

Aligos Therapeutics, Inc. - Common stock  (ALGS) 
PDF Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size increased to optimize powe [Read more]